Related Experiment Video
Updated: Feb 20, 2026
08:08
Cardiopulmonary Bypass in a Mouse Model: A Novel Approach
Published on: September 22, 2017
11.7K
New Technology Mimics Physiologic Pulsatile Flow During Cardiopulmonary Bypass.
Gengo Sunagawa1, Jamshid H Karimov1, Raymond Dessoffy1
1Department of Biomedical Engineering, Lerner Research Institute, Cleveland, OH.
Artificial Organs
|October 28, 2017
Summary
The VentriFlo True Pulse Pump successfully mimicked human arterial waveforms in piglets during cardiopulmonary bypass. This pulsatile pump demonstrated safety and feasibility for future clinical studies.
Area of Science:
- Cardiovascular Research
- Biomedical Engineering
- Surgical Technology
Background:
- Cardiopulmonary bypass (CPB) traditionally uses nonpulsatile blood pumps.
- Mimicking natural arterial waveforms may offer clinical advantages.
- The VentriFlo True Pulse Pump is designed to generate pulsatile flow.
Purpose of the Study:
- To assess the feasibility and safety of the VentriFlo True Pulse Pump.
- To compare hemodynamic parameters between pulsatile and nonpulsatile CPB.
- To evaluate organ perfusion during prolonged CPB with the VentriFlo pump.
Main Methods:
- A pilot study involving four piglets (3 with VentriFlo, 1 control with ROTAFLOW).
- Monitoring hemodynamics during 6-hour CPB and 2-hour post-CPB weaning.
- Analysis of arterial waveforms, pump flows, plasma free hemoglobin, and systemic oxygen extraction.
Main Results:
- VentriFlo generated physiologic arterial waveforms with a pulse pressure of 24.6 ± 5.7 mm Hg.
- Comparable pump flows and plasma free hemoglobin levels were observed between groups.
- Systemic oxygen extraction was slightly higher with VentriFlo (63.2% vs. 55.4%).
- Histology confirmed no ischemic changes or thromboembolism.
Conclusions:
- The VentriFlo True Pulse Pump is feasible and safe for CPB.
- It effectively generates pulsatile flow, maintaining adequate organ perfusion.
- Further studies are warranted to explore potential clinical benefits.
